Facet Biotech News

Top US stock recommendations of the day: ABBOTT LABORATORIES: Goldman Sachs upgrades to BUY from neutral.

Most of us go to the doctor for a checkup once per year. Many of us visit our dentists twice per year.

REVA Medical, Inc. is pleased to announce that Michel Vanbrabant has been appointed Managing Director International for the Company.

If I could send a message back in time to my younger self, I would only need to use four words, "Keep it simple, Stupid!" This is great advice for life in general, but especially good advice when investing one's own money.

This is the first Humira lawsuit filed against Abbott to go to trial. "We are honored that a jury of twelve people looked at the evidence and agreed that Abbott failed to do what the law requires," said Tietz attorney , Delores began experiencing chest pain and fevers.

Gleacher & Company announced its earnings results on Thursday. The company reported earnings per share for the quarter, missing the analysts' consensus estimate of by $0.12, Analyst Ratings Network reports.

Area companies have made the Fortune 500 list for 2013, including Abbott Laboratories and CDW.

A live audio webcast will be accessible through Abbott's Investor Relations Web site at www.abbottinvestor.com . An archived edition of the presentation will be available later that day.

These individuals will focus on High Yield and Investment Grade Sales and Trading, and building out the firm's credit platform.

A new generation of drug industry chief executives is stepping up plans to restructure their businesses by divesting slower-growing and maturing operations, opening up new opportunities for deal-makers. Bankers speaking at the Reuters Health Summit said the success of transactions such as Pfizer Inc's divestitures of noncore assets and Abbott ... (more)

NestlA© USA and Mead Johnson Nutrition have dismissed calls to remove genetically-modified organisms ingredients from their infant formula products in the US - citing the approved use of GMOs by several national and global regulatory bodies.

's stock had its "market perform" rating restated by analysts at Sanford C. Bernstein in a research report issued to clients and investors on Thursday, Analyst Ratings.Net reports.

An Abbott Laboratories shareholder proposal to remove genetically-modified organisms from its natural products - including its Similac infant formula range - has been rejected, the Illinois-based company has revealed.

The single, easiest way to keep track of all the stocks that matter... Your own personalized stock watchlist! It's a 100% FREE Motley Fool service... Abbott Laboratories stock hit a high in October of last year of 72.47, but when the new year hit, the company split in two, spinning its drug assets into AbbVie .

AbbVie Inc. topped Wall Street expectations in its first three months as a standalone company and shares bounced within a penny of a record high Friday.

AbbVie Inc. reported earnings that beat analysts' estimates on higher sales of the rheumatoid arthritis treatment Humira in the first quarter since the drugmaker was split from parent Abbott Laboratories.

AbbVie Inc. reported slightly better than expected quarterly results today, fueled by surging sales of its Humira treatment for rheumatoid arthritis.

Abbott Laboratories, one of the world's top ten pharmaceutical and nutritional product companies, is using genetically modified corn and soy in its popular Similac infant formula and investors don't like it.

April 23 - Shareholders of Abbott Laboratories will vote on whether the manufacturer of Similac, a leading brand of infant formula, should adopt a policy of sourcing ingredients that have not been genetically engineered.

Keep track of the stocks that matter to you. Help yourself with the Fool's FREE and easy new watchlist service today.